Literature DB >> 14660270

Etanercept therapy in patients with autoimmunity and hepatitis C.

M Khanna1, M A Shirodkar, A B Gottlieb.   

Abstract

Accumulated data suggest that etanercept may be a therapeutic option in patients with hepatitis C and coexisting autoimmune disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis and ankylosing spondylitis. Additionally, etanercept may actually be of benefit, when used in combination with standard treatments, for hepatitis C.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14660270     DOI： 10.1080/09546630310020470

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


  14 in total

Review 1.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 4.  Management of psoriasis patients with hepatitis B or hepatitis C virus infection.

Authors:  Claudio Bonifati; Viviana Lora; Dario Graceffa; Lorenzo Nosotti
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

5.  Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.

Authors:  Agustin Castiella; Eva Zapata; M Isabel Lucena; Raúl J Andrade
Journal:  World J Hepatol       Date:  2014-04-27

6.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

Review 7.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 8.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases.

Authors:  S Aslanidis; T Vassiliadis; A Pyrpasopoulou; I Douloumpakas; C Zamboulis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 3.650

10.  Update on the use of etanercept across a spectrum of rheumatoid disorders.

Authors:  Bernard Combe
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.